202 related articles for article (PubMed ID: 28339198)
1. Discovery of 4-((3'R,4'S,5'R)-6″-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2″-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3″-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development.
Aguilar A; Lu J; Liu L; Du D; Bernard D; McEachern D; Przybranowski S; Li X; Luo R; Wen B; Sun D; Wang H; Wen J; Wang G; Zhai Y; Guo M; Yang D; Wang S
J Med Chem; 2017 Apr; 60(7):2819-2839. PubMed ID: 28339198
[TBL] [Abstract][Full Text] [Related]
2. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors.
Zhao Y; Liu L; Sun W; Lu J; McEachern D; Li X; Yu S; Bernard D; Ochsenbein P; Ferey V; Carry JC; Deschamps JR; Sun D; Wang S
J Am Chem Soc; 2013 May; 135(19):7223-34. PubMed ID: 23641733
[TBL] [Abstract][Full Text] [Related]
3. A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53
Skalniak L; Twarda-Clapa A; Neochoritis CG; Surmiak E; Machula M; Wisniewska A; Labuzek B; Ali AM; Krzanik S; Dubin G; Groves M; Dömling A; Holak TA
FEBS J; 2019 Apr; 286(7):1360-1374. PubMed ID: 30715803
[TBL] [Abstract][Full Text] [Related]
4. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
[TBL] [Abstract][Full Text] [Related]
5. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
Aguilar A; Sun W; Liu L; Lu J; McEachern D; Bernard D; Deschamps JR; Wang S
J Med Chem; 2014 Dec; 57(24):10486-98. PubMed ID: 25496041
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule MDM2-p53 inhibitors: recent advances.
Zhang B; Golding BT; Hardcastle IR
Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
[TBL] [Abstract][Full Text] [Related]
7. Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.
Miyazaki M; Uoto K; Sugimoto Y; Naito H; Yoshida K; Okayama T; Kawato H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
Bioorg Med Chem; 2015 May; 23(10):2360-7. PubMed ID: 25882531
[TBL] [Abstract][Full Text] [Related]
8. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
Zhao Y; Yu S; Sun W; Liu L; Lu J; McEachern D; Shargary S; Bernard D; Li X; Zhao T; Zou P; Sun D; Wang S
J Med Chem; 2013 Jul; 56(13):5553-61. PubMed ID: 23786219
[TBL] [Abstract][Full Text] [Related]
9. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
[TBL] [Abstract][Full Text] [Related]
11. Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.
Li Y; Yang J; Aguilar A; McEachern D; Przybranowski S; Liu L; Yang CY; Wang M; Han X; Wang S
J Med Chem; 2019 Jan; 62(2):448-466. PubMed ID: 30525597
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.
Gollner A; Rudolph D; Arnhof H; Bauer M; Blake SM; Boehmelt G; Cockroft XL; Dahmann G; Ettmayer P; Gerstberger T; Karolyi-Oezguer J; Kessler D; Kofink C; Ramharter J; Rinnenthal J; Savchenko A; Schnitzer R; Weinstabl H; Weyer-Czernilofsky U; Wunberg T; McConnell DB
J Med Chem; 2016 Nov; 59(22):10147-10162. PubMed ID: 27775892
[TBL] [Abstract][Full Text] [Related]
14. Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.
Rew Y; Sun D; Yan X; Beck HP; Canon J; Chen A; Duquette J; Eksterowicz J; Fox BM; Fu J; Gonzalez AZ; Houze J; Huang X; Jiang M; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Saiki AY; Shaffer P; Wang YC; Wortman S; Yakowec P; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2014 Dec; 57(24):10499-511. PubMed ID: 25384157
[TBL] [Abstract][Full Text] [Related]
15. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
[TBL] [Abstract][Full Text] [Related]
16. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
17. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
Sun D; Li Z; Rew Y; Gribble M; Bartberger MD; Beck HP; Canon J; Chen A; Chen X; Chow D; Deignan J; Duquette J; Eksterowicz J; Fisher B; Fox BM; Fu J; Gonzalez AZ; Gonzalez-Lopez De Turiso F; Houze JB; Huang X; Jiang M; Jin L; Kayser F; Liu JJ; Lo MC; Long AM; Lucas B; McGee LR; McIntosh J; Mihalic J; Oliner JD; Osgood T; Peterson ML; Roveto P; Saiki AY; Shaffer P; Toteva M; Wang Y; Wang YC; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Yu M; Zhao X; Zhou J; Zhu J; Olson SH; Medina JC
J Med Chem; 2014 Feb; 57(4):1454-72. PubMed ID: 24456472
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
[TBL] [Abstract][Full Text] [Related]
19. Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.
D'Alessandro PL; Buschmann N; Kaufmann M; Furet P; Baysang F; Brunner R; Marzinzik A; Vorherr T; Stachyra TM; Ottl J; Lizos DE; Cobos-Correa A
Angew Chem Int Ed Engl; 2016 Dec; 55(52):16026-16030. PubMed ID: 27874234
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Holzer P; Masuya K; Furet P; Kallen J; Valat-Stachyra T; Ferretti S; Berghausen J; Bouisset-Leonard M; Buschmann N; Pissot-Soldermann C; Rynn C; Ruetz S; Stutz S; Chène P; Jeay S; Gessier F
J Med Chem; 2015 Aug; 58(16):6348-58. PubMed ID: 26181851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
